HDM1002

Asset

Activates GLP-1 receptors to promote satiety and reduce body weight.

Stage: Phase 2
Modality: Small molecule
Target: GLP1R; 2
Indications: 0
Trials: 2
Developers

Indications

2

Obesity
Phase 2, doi.org, 5 Jun 2026
Overweight
Phase 2, doi.org, 5 Jun 2026

In the full profile

Targets and what it contains1
Owner and partners2
Evidence for its targets2
Competitors12
Signals2

Every asset’s record: target, stage, trials and the evidence behind it.